Factors Determining Anthracycline Use in Hormone Receptor Positive, Early Stage Breast Cancer

Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2019.01.012
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Progesterone Receptor Expression in Proliferating Cancer Cells of Hormone-Receptor-Positive Breast Cancer

Tumor Biology
MedicineCancer Research
2018English

Optimal Treatment of Early Stage HER2-positive Breast Cancer

Cancer
Cancer ResearchOncology
2018English

Prognostic and Predictive Factors in Early-Stage Breast Cancer

Oncologist
Cancer ResearchMedicineOncology
2004English

A Multigene Predictor of Metastatic Outcome in Early Stage Hormone Receptor-Negative and Triple-Negative Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2010English

Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor–Positive, HER2-Negative Early Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2018English

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Geburtshilfe und Frauenheilkunde
GynecologyMidwiferyMaternityObstetrics
2019English

Early Stage Breast Cancer

Oncology Reports
MedicineCancer ResearchOncology
1997English

Medical Oncologists’ Perception of Anti-Estrogen Therapy Benefit in Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer

Annals of Oncology
MedicineOncologyHematology
2018English

Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy as (Neo)Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2–Positive Early-Stage Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy